<DOC>
	<DOCNO>NCT01904292</DOCNO>
	<brief_summary>This open-label , multicenter study evaluate pharmacokinetics , pharmacodynamics , safety subcutaneously administer tocilizumab participant Systemic Juvenile Idiopathic Arthritis ( sJIA ) . Participants body weight less ( &lt; ) 30 kilogram ( kg ) receive subcutaneous ( SC ) tocilizumab dose every 2 week ( Q2W ) participant body weight great equal ( &gt; = ) 30 kg receive weekly ( QW ) , 52 week . Tocilizumab administer every 10 day pre-planned interim analysis perform change Q2W participant body weight &lt; 30 kg .</brief_summary>
	<brief_title>A Study Subcutaneously Administered Tocilizumab Participants With Systemic Juvenile Idiopathic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Diagnosis sJIA accord International League Associations Rheumatology ( ILAR ) classification History inadequate clinical response ( opinion treat physician ) NonSteroidal AntiInflammatory Drugs ( NSAIDs ) corticosteroid If participant receive previous treatment biologic agent tocilizumab , must discontinue accord timeline define protocol prior baseline visit Participants currently receive tocilizumab intravenous ( IV ) route administration wellcontrolled disease require period discontinuation IV tocilizumab first dose SC tocilizumab administer date next IV tocilizumab infusion would due Concurrent treatment Disease Modifying AntiRheumatic Drugs ( DMARDs ) include methotrexate ( MTX ) , NSAIDs , oral corticosteroid permit discretion investigator Participants reproductive potential must willing use highly effective contraceptive method Prior discontinuation IV tocilizumab inadequate clinical response safety event ( include hypersensitivity ) Participants poorly control disease ( opinion treat physician ) despite current treatment IV tocilizumab sJIA well control treatment agent tocilizumab ( Juvenile Arthritis Disease Activity Score 71 Joints [ JADAS71 ] less equal [ &lt; = ] 3.8 fever ) Participants wheelchairbound bedridden Any autoimmune , rheumatic disease , overlap syndrome sJIA Lack recovery recent surgery interval &lt; 6 week since surgery time screen visit Females pregnant , lactating , intend become pregnant study conduct Any significant concurrent medical surgical condition would jeopardize participant 's safety ability complete study Known Human Immunodeficiency Virus ( HIV ) infection acquire form immune compromise inborn condition characterize compromise immune system History alcohol , drug , chemical abuse within 6 month screen Any active acute , subacute , chronic , recurrent bacterial , viral , systemic fungal infection major episode infection require hospitalization treatment screen treatment IV antibiotic complete within 4 week screen visit oral antibiotic complete within 2 week screen visit History atypical tuberculosis ( TB ) active TB require treatment within 2 year prior screen visit Positive TB test screen unless treat antiTB therapy least 4 week prior receive study drug History reactivation new onset systemic infection herpes zoster EpsteinBarr virus within 2 month screen visit Hepatitis B surface antigen hepatitis C antibody positivity chronic viral autoimmune hepatitis History concurrent serious gastrointestinal disorder ulcer inflammatory bowel disease , Crohn 's disease , ulcerative colitis , symptomatic low gastrointestinal condition History current cancer lymphoma Uncontrolled diabetes mellitus elevate glycosylated hemoglobin Macrophage activation syndrome ( MAS ) within 3 month screen visit Inadequate hematologic , renal liver function</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>